Health Condition 1: N22- Calculus of urinary tract in diseases classified elsewhere
Conditions
Interventions
Intervention1: Tab. Mirabegron 25mg OD orally for 4 weeks: efficacy 3 different drugs
Control Intervention1: Tab. Tamsulosin 0.4mg OD orally for 4 weeks: Efficacy of 3 different drugs
Control Interven
Sponsors
AIIMS JODHPUR
Eligibility
Inclusion criteria
Inclusion criteria: Presence of a Double J stent in the urinary tract. Complaints of lower urinary tract complaints.
Exclusion criteria
Exclusion criteria: Previous treatment with any of the study medications. Contraindications to the use of any study medication. Presence of other significant urinary tract pathology. Pregnancy or breastfeeding. Any condition that may interfere with the study assessments or participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Using the Ureteric stent symptom score (USSQ), we will be investigating the efficacy of tamsulosin, solifenacin, and mirabegron in lowering DJ stent related symptoms in this study.Timepoint: Baseline, 2 weeks and 4 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the impact of LUTS on quality of life (QOL) in patients with DJ stent. To identify the factors that increase the incidence of LUTS in patients with DJ stent. Timepoint: Baseline, 2 weeks & 4 weeks | — |
Countries
India
Contacts
Public ContactShiv Charan Navriya
AIIMS Jodhpur
Outcome results
None listed